Prodomains regulate the synthesis, extracellular localisation and activity of TGF-β superfamily ligands

Growth Factors

Volumn 29, Issue 5, 2011, Pages 174-186

  Harrison, Craig A ^a   Al Musawi, Sara L ^a   Walton, Kelly L ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Activin; Bone morphogenetic protein; Growth differentiation factor; Inhibin; Prodomain; Transforming growth factor

Indexed keywords

ACTIVIN A; BINDING PROTEIN; BONE MORPHOGENETIC PROTEIN 5; BONE MORPHOGENETIC PROTEIN 6; FIBRILLIN; FIBRILLIN 1; FIBRILLIN 2; GROWTH DIFFERENTIATION FACTOR; GROWTH DIFFERENTIATION FACTOR 5; INHIBIN A; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; MYOSTATIN; PERLECAN; PROTEIN GDF 11; PROTEIN LTBP 3; PROTEIN LTBP 4; PROTEIN PCSK 3; PROTEN LTBP 1; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALPHA HELIX; ARTICLE; BIOAVAILABILITY; CELLULAR DISTRIBUTION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

ACTIVINS; BONE MORPHOGENETIC PROTEINS; EXTRACELLULAR MATRIX PROTEINS; GROWTH DIFFERENTIATION FACTORS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; INHIBINS; LIGANDS; MICROFILAMENT PROTEINS; PROTEIN BINDING; PROTEIN SORTING SIGNALS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; TGF-BETA SUPERFAMILY PROTEINS;

EID: 80052874703     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2011.608666     Document Type: Article

References (111)

1. Akpan I, GoncalvesMD, Dhir R, Yin X, Pistilli EE, Bogdanovich S, Khurana TS, Ucran J, Lachey J, Ahima RS. 2009. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond) 33:1265-1273.
2. Anderson SB, Goldberg AL, Whitman M. 2008. Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. J Biol Chem 283:7027-7035.
3. Annes JP, Chen Y, Munger JS, Rifkin DB. 2004. Integrin alphaVbeta6-mediated activation of latent BRI-βeta requires the latent BRI-βeta binding protein-1. J Cell Biol 165: 723-734. (Pubitemid 38765773)
4. Annes JP, Rifkin DB, Munger JS. 2002. The integrin alphaVbeta6 binds and activates latent BRI-β3. FEBS Lett 511:65-68. (Pubitemid 34127824)
5. Antenos M, Zhu J, Jetly NM, Woodruff TK. 2008. An activin/furin regulatory loop modulates the processing and secretion of inhibin alpha-and beta-subunit dimers in pituitary gonadotrope cells. J Biol Chem 283:33059-33068.
6. Asai-Coakwell M, French CR, Ye M, Garcha K, Bigot K, Perera AG, Staehling-Hampton K, Mema SC, Chanda B, Mushegian A, Bamforth S, Doschak MR, Li G, Dobbs MB, Giampietro PF, Brooks BP, Vijayalakshmi P, Sauvé Y, Abitbol M, Sundaresan P, van Heyningen V, Pourquié O, Underhill TM, Waskiewicz AJ, Lehmann OJ. 2009. Incomplete penetrance and phenotypic variability characterize Gdf6-attributable oculo-skeletal phenotypes. Hum Mol Genet 18:1110-1121.
7. Bakrania P, Efthymiou M, Klein JC, Salt A, Bunyan DJ, Wyatt A, Ponting CP, Martin A, Williams S, Lindley V, Gilmore J, Restori M, Robson AG, Neveu MM, Holder GE, Collin JR, Robinson DO, Farndon P, Johansen-Berg H, Gerrelli D, Ragge NK. 2008. Mutations in BMP4 cause eye, brain, and digit developmental anomalies: Overlap between the BMP4 and hedgehog signaling pathways. Am J Hum Genet 82:304-319.
8. Bauskin AR, Brown DA, Junankar S, Rasiah KK, Eggleton S, Hunter M, Liu T, Smith D, Kuffner T, Pankhurst GJ, Johnen H, Russell PJ, Barret W, Stricker PD, Grygiel JJ, Kench JG, Henshall SM, Sutherland RL, Breit SN. 2005. The propeptide mediates formation of stromal stores of PROMIC-1: Role in determining prostate cancer outcome. Cancer Res 65: 2330-2336. (Pubitemid 40490143)
9. Beck S, Le Good JA, Guzman M, Ben Haim N, RoyK, Beermann F, Constam DB. 2002. Extraembryonic proteases regulate Nodal signalling during gastrulation. Nat Cell Biol 4:981-985. (Pubitemid 35469429)
10. Belville C, van Vlijmen H, Ehrenfels C, Pepinsky B, Rezaie AR, Picard JY, Josso N, di Clemente N, Cate RL. 2004. Mutations of the anti-mullerian hormone gene in patients with persistent mullerian duct syndrome: Biosynthesis, secretion, and processing of the abnormal proteins and analysis using a threedimensional model. Mol Endocrinol 18:708-721. (Pubitemid 38328214)
11. Blanchet MH, Le Good JA, Mesnard D, Oorschot V, Baflast S, Minchiotti G, Klumperman J, Constam DB. 2008. Cripto recruits Furin and PACE4 and controls Nodal trafficking during proteolytic maturation. EMBO J 27:2580-2591.
12. Blobe GC, Schiemann WP, Lodish HF. 2000. Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350-1358. (Pubitemid 30408720)
13. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS. 2005. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 19:543-549. (Pubitemid 40471245)
14. Bottinger EP, Factor VM, Tsang ML, Weatherbee JA, Kopp JB, Qian SW, Wakefield LM, Roberts AB, Thorgeirsson SS, Sporn MB. 1996. The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci USA 93:5877-5882.
15. Brunner AM, Marquardt H, Malacko AR, Lioubin MN, Purchio AF. 1989. Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. J Biol Chem 264:13660-13664. (Pubitemid 19198449)
16. Buzzard JJ, Loveland KL, O'Bryan MK, O'Connor AE, Bakker M, Hayashi T, Wreford NG, Morrison JR, de Kretser DM. 2004. Changes in circulating and testicular levels of inhibin A and B and activin A during postnatal development in the rat. Endocrinology 145:3532-3541. (Pubitemid 38830025)
17. Chen Y, Ali T, Todorovic V, O'Leary JM, Kristina Downing A, Rifkin DB. 2005. Amino acid requirements for formation of the BRI-βeta-latent BRI-βeta binding protein complexes. J Mol Biol 345:175-186. (Pubitemid 39572834)
18. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC. 2007. Angiotensin II type 1 receptor blockade attenuates BRI-βeta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13:204-210.
19. Constam DB. 2009. Riding shotgun: A dual role for the epidermal growth factor-Cripto/FRL-1/Cryptic protein Cripto in Nodal trafficking. Traffic 10:783-791.
20. Constam DB, Robertson EJ. 1999. Regulation of bone morphogenetic protein activity by pro domains and proprotein convertases. J Cell Biol 144:139-149. (Pubitemid 29047017)
21. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. 1998. Thrombospondin-1 is a major activator of BRI-βeta1 in vivo. Cell 93:1159-1170. (Pubitemid 28307421)
22. di Clemente N, Jamin SP, Lugovskoy A, Carmillo P, Ehrenfels C, Picard JY, Whitty A, Josso N, Pepinsky RB, Cate RL. 2010. Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from BRI-βeta. Mol Endocrinol 24:2193-2206.
23. di Pasquale E, Beck-Peccoz P, Persani L. 2004. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet 75:106-111. (Pubitemid 38801906)
24. di Pasquale E, Rossetti R, Marozzi A, Bodega B, Borgato S, Cavallo L, Einaudi S, Radetti G, Russo G, Sacco M, Wasniewska M, Cole T, Beck-Peccoz P, Nelson LM, Persani L. 2006. Identification of new variants of human BMP15 gene in a large cohort of women with premature ovarian failure. J Clin Endocrinol Metab 91:1976-1979.
25. Dixit H, Rao LK, Padmalatha VV, Kanakavalli M, Deenadayal M, Gupta N, Chakrabarty B, Singh L. 2006. Missense mutations in the BMP15 gene are associated with ovarian failure. Hum Genet 119:408-415.
26. Douzgou S, Lehmann K, Mingarelli R, Mundlos S, Dallapiccola B. 2008. Compound heterozygosity for GDF5 in Du Pan type chondrodysplasia. Am J Med Genet A 146A:2116-2121.
27. Dube JL, Wang P, Elvin J, Lyons KM, Celeste AJ, Matzuk MM. 1998. The bone morphogenetic protein 15 gene is X-linked and expressed in oocytes. Mol Endocrinol 12:1809-1817. (Pubitemid 28544177)
28. Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R. 1995. Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 270:10618-10624.
29. Essalmani R, Zaid A, Marcinkiewicz J, Chamberland A, Pasquato A, Seidah NG, Prat A. 2008. In vivo functions of the proprotein convertase PC5/6 during mouse development: Gdf11 is a likely substrate. Proc Natl Acad Sci USA 105:5750-5755. (Pubitemid 351758444)
30. Everman DB, Bartels CF, Yang Y, Yanamandra N, Goodman FR, Mendoza-Londono JR, Savarirayan R, White SM, Graham JM, Jr, Gale RP, Svarch E, Newman WG, Kleckers AR, Francomano CA, Govindaiah V, Singh L, Morrison S, Thomas JT, Warman ML. 2002. The mutational spectrum of brachydactyly type C. Am J Med Genet 112:291-296.
31. Fairlie WD, Zhang HP, Wu WM, Pankhurst SL, Bauskin AR, Russell PK, Brown PK, Breit SN. 2001. The propeptide of the transforming growth factor-βeta superfamily member, macrophage inhibitory cytokine-1 (MIC-1), is a multifunctional domain that can facilitate protein folding and secretion. J Biol Chem 276:16911-16918.
32. Ge G, Greenspan DS. 2006. BMP1 controls BRI-β1 activation via cleavage of latent BRI-β-βinding protein. J Cell Biol 175: 111-120. (Pubitemid 44537203)
33. Ge G, Hopkins DR, Ho WB, Greenspan DS. 2005. GDF11 forms a bone morphogenetic protein 1-activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells. Mol Cell Biol 25:5846-5858. (Pubitemid 40946542)
34. Gebbia M, Ferrero GB, Pilia G, Bassi MT, Aylsworth A, Penman-Splitt M, Bird LM, Bamforth JS, Burn J, Schlessinger D, Nelson DL, Casey B. 1997. X-linked situs abnormalities result from mutations in ZIC3. Nat Genet 17:305-308. (Pubitemid 27475993)
35. Gleizes PE, Beavis RC, Mazzieri R, Shen B, Rifkin DB. 1996. Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-βeta binding protein-1 that mediates bonding to the latent transforming growth factorbeta1. J Biol Chem 271:29891-29896. (Pubitemid 26389623)
36. Goldman DC, Hackenmiller R, Nakayama T, Sopory S, Wong C, Kulessa H, Christian JL. 2006. Mutation of an upstream cleavage site in the BMP4 prodomain leads to tissue-specific loss of activity. Development 133:1933-1942. (Pubitemid 43881259)
37. Gonzalez-Rodriguez J, Pelcastre EL, Tovilla-Canales JL, Garcia-Ortiz JE, Amato-Almanza M, Villanueva-Mendoza C, Espinosa-Mattar Z, Zenteno JC. 2010. Mutational screening of CHX10, GDF6, OTX2, RAX and SOX2 genes in 50 unrelated microphthalmia-anophthalmia-coloboma (MAC) spectrum cases. Br J Ophthalmol 94:1100-1104.
38. Gray AM, Mason AJ. 1990. Requirement for activin A and transforming growth factor-βeta 1 pro-regions in homodimer assembly. Science 247:1328-1330.
39. Gregory KE, Ono RN, Charbonneau NL, Kuo CL, Keene DR, Bachinger HP, Sakai LY. 2005. The prodomain of BMP-7 targets the BMP-7 complex to the extracellular matrix. J Biol Chem 280:27970-27980. (Pubitemid 41076914)
40. Habashi JP, JudgeDP, Holm TM, CohnRD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. 2006. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312:117-121.
41. HamrickMW, Arounleut P, Kellum E, Cain M, ImmelD, Liang LF. 2010. Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury. J Trauma 69: 579-583.
42. Heng S, Paule S, Hardman B, Li Y, Singh H, Rainczuk A, Stephens AN, Nie G. 2010. Posttranslational activation of bone morphogenetic protein 2 is mediated by proprotein convertase 6 during decidualization for pregnancy establishment. Endocrinology 151:3909-3917.
43. Ho DM, Yeo CY, Whitman M. 2010. The role and regulation of GDF11 in Smad2 activation during tailbud formation in the Xenopus embryo. Mech Dev 127:485-495.
44. Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, van Erp C, Lindsay ME, Kim D, Schoenhoff F, Cohn RD, Loeys BL, Thomas CJ, Patnaik S, Marugan JJ, Judge DP, Dietz HC. 2011. Noncanonical BRI-β signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 332: 358-361.
45. Imbeaud S, Carre-Eusebe D, Rey R, Belville C, Josso N, Picard JY. 1994. Molecular genetics of the persistent mullerian duct syndrome: A study of 19 families. Hum Mol Genet 3:125-131.
46. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, Charbonneau NL, Reinhardt DP, Rifkin DB, Sakai LY. 2003. Latent transforming growth factor beta-βinding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 278:2750-2757. (Pubitemid 36801356)
47. Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van Maldergem L, Ralston S, Guañabens N, Migone N, Wientroub S, Divizia MT, Bergmann C, Bennett C, Simsek S, Melancon S, Cundy T, Van HulW. 2006. Camurati-Engelmann disease: Review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet 43:1-11. (Pubitemid 43099989)
48. Jenkins G. 2008. The role of proteases in transforming growth factor-βeta activation. Int J Biochem Cell Biol 40: 1068-1078.
49. Jiang MS, Liang LF,Wang S, Ratovitski T, Holmstrom J, Barker C, Stotish R. 2004. Characterization and identification of the inhibitory domain of GDF-8 propeptide. Biochem Biophys Res Commun 315:525-531. (Pubitemid 38229375)
50. Kusakabe M, Cheong PL, Nikfar R, McLennan IS, Koishi K. 2008. The structure of the BRI-βeta latency associated peptide region determines the ability of the proprotein convertase furin to cleave BRI-βetas. J Cell Biochem 103:311-320.
51. Lau CP, Ledger WL, Groome NP, Barlow DH, Muttukrishna S. 1999. Dimeric inhibins and activin A in human follicular fluid and oocyte-cumulus culture medium. Hum Reprod 14: 2525-2530. (Pubitemid 29473924)
52. Lee SJ. 2008. Genetic analysis of the role of proteolysis in the activation of latent myostatin. PLoS One 3:e1628.
53. Lee SJ, Reed LA, Davies MV, Girgenrath S, Goad ME, Tomkinson KN, Wright JF, Barker C, Ehrmantraut G, Holmstrom J, Trowell B, Gertz B, Jiang MS, Sebald SM, Matzuk M, Li E, Liang LF, Quattlebaum E, Stotish RL, Wolfman NM. 2005. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 102:18117-18122. (Pubitemid 41798511)
54. Li S, Shimono C, Norioka N, Nakano I, Okubo T, Yagi Y, Hayashi M, Sato Y, Fujisaki H, Hattori S, Sugiura N, Kimata K, Sekiguchi K. 2010a. Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity. J Biol Chem 285:36645-36655.
55. Li Z, Zhao B, Kim YS, Hu CY, Yang J. 2010b. Administration of a mutated myostatin propeptide to neonatal mice significantly enhances skeletal muscle growth. Mol Reprod Dev 77:76-82.
56. Lindsay ME, Dietz HC. 2011. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature 473:308-316.
57. Little SC, Mullins MC. 2009. Bone morphogenetic protein heterodimers assemble heteromeric type I receptor complexes to pattern the dorsoventral axis. Nat Cell Biol 11:637-643.
58. Makanji Y, Walton KL, Chan KL, Gregorevic P, Robertson DM, Harrison CA. 2011. Generation of a specific activin antagonist by modification of the activin A propeptide. Endocrinology July 12, doi: 10.1210/en.2011-1052.
59. Mason AJ, Hayflick JS, Ling N, Esch F, Ueno N, Ying SY, Guillemin R, Niall H, Seeburg PH. 1985. Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-βeta. Nature 318:659-663. (Pubitemid 16172414)
60. Matsakas A, Foster K, Otto A, Macharia R, Elashry MI, Feist S, Graham I, Foster H, Yaworsky P, Walsh F, Dickson G, Patel K. 2009. Molecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult mice. Neuromuscul Disord 19:489-499.
61. McIntosh CJ, Lun S, Lawrence S, Western AH, McNatty KP, Juengel JL. 2008. The proregion of mouse BMP15 regulates the cooperative interactions of BMP15 and GDF9. Biol Reprod 79: 889-896.
62. McPherron AC, Lawler AM, Lee SJ. 1999. Regulation of anterior/ posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat Genet 22:260-264. (Pubitemid 29297252)
63. McPherron AC, Lee SJ. 1997. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 94: 12457-12461. (Pubitemid 27492550)
64. Miyazono K, Hellman U, Wernstedt C, Heldin CH. 1988. Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem 263:6407-6415.
65. Mohapatra B, Casey B, Li H, Ho-Dawson T, Smith L, Fernbach SD, Molinari L, Niesh SR, Jefferies JL, Craigen WJ, Towbin JA, Belmont JW, Ware SM. 2009. Identification and functional characterization of NODAL rare variants in heterotaxy and isolated cardiovascular malformations. Hum Mol Genet 18:861-871.
66. Munger JS, Harpel JG, Giancotti FG, Rifkin DB. 1998. Interactions between growth factors and integrins: Latent forms of transforming growth factor-βeta are ligands for the integrin alphavbeta1. Mol Biol Cell 9:2627-2638. (Pubitemid 28425898)
67. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL,Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D. 1999. The integrin alpha v beta 6 binds and activates latent BRI-β beta 1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell 96:319-328. (Pubitemid 29077586)
68. Nelsen SM, Christian JL. 2009. Site-specific cleavage of BMP4 by furin, PC6, and PC7. J Biol Chem 284:27157-27166.
69. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. 2003. Dysregulation of BRI-βeta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33:407-411. (Pubitemid 36278859)
70. Nistala H, Lee-Arteaga S, Smaldone S, Siciliano G, Carta L, Ono RN, Sengle G, Arteaga-Solis E, Levasseur R, Ducy P, Sakai LY, Karsenty G, Ramirez F. 2010. Fibrillin-1 and -2 differentially modulate endogenous BRI-βeta and BMP bioavailability during bone formation. J Cell Biol 190:1107-1121.
71. Noor A, Windpassinger C, Vitcu I, Orlic M, Rafiq MA, Khalid M, Malik MN, Ayub M, Alman B, Vincent JB. 2009. Oligodontia is caused by mutation in LTBP3, the gene encoding latent BRI-βeta binding protein 3. Am J Hum Genet 84:519-523.
72. Nunes I, Gleizes PE, Metz CN, Rifkin DB. 1997. Latent transforming growth factor-βeta binding protein domains involved in activation and transglutaminase-dependent crosslinking of latent transforming growth factor-βeta. J Cell Biol 136: 1151-1163. (Pubitemid 27131745)
73. PearsallRS,Canalis E,Cornwall-βradyM,UnderwoodKW,HaigisB, Ucran J, Kumar R, Pobre E, Grinberg A, Werner ED, Glatt V, Stadmeyer L, Smith D, Seehra J, Bouxsein ML. 2008. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA 105:7082-7087. (Pubitemid 351754533)
74. Ploger F, Seemann P, Schmidt-von Kegler M, Lehmann K, Seidel J, Kjaer KW, Pohl J, Mundlos S. 2008. Brachydactyly type A2 associated with a defect in proGDF5 processing. Hum Mol Genet 17:1222-1233. (Pubitemid 351566959)
75. Qiao C, Li J, Jiang J, Zhu X, Wang B, Xiao X. 2008. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther 19:241-254.
76. Rifkin DB. 2005. Latent transforming growth factor-βeta ( BRI-β) binding proteins: Orchestrators of BRI-βeta availability. J Biol Chem 280:7409-7412. (Pubitemid 40349631)
77. Robertson I, Jensen S, Handford P. 2010. TB domain proteins: Evolutionary insights into the multifaceted roles of fibrillins and LTBPs. Biochem J 433:263-276.
78. Robinson PN, Arteaga-Solis E, Baldock C, Collod-βéroud G, Booms P, De Paepe A, Dietz HC, Guo G, Handford PA, Judge DP, Kielty CM, Loeys B, Milewicz DM, Ney A, Ramirez F, Reinhardt DP, Tiedemann K, Whiteman P, Godfrey M. 2006. The molecular genetics of Marfan syndrome and related disorders. J Med Genet 43:769-787. (Pubitemid 44654735)
79. Rossetti R, Di Pasquale E, Marozzi A, Bione S, Toniolo D, Grammatico P, Nelson LM, Beck-Peccoz P, Persani L. 2009. BMP15 mutations associated with primary ovarian insufficiency cause a defective production of bioactive protein. Hum Mutat 30:804-810.
80. Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, Seehra J, Yang Y, Condon CH, Sherman ML. 2009. Single-dose, randomized, double-βlind, placebocontrolled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 24:744-752.
81. Saharinen J, Keski-Oja J. 2000. Specific sequence motif of 8-Cys repeats of BRI-βeta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent BRI-βeta. Mol Biol Cell 11:2691-2704. (Pubitemid 30645036)
82. Saharinen J, Taipale J, Keski-Oja J. 1996. Association of the small latent transforming growth factor-βeta with an eight cysteine repeat of its binding protein LTBP-1. EMBO J 15:245-253. (Pubitemid 26029204)
83. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. 1994. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-βeta in a chemically defined system. J Biol Chem 269:26775-26782. (Pubitemid 24332871)
84. Sengle G, Charbonneau NL, Ono RN, Sasaki T, Alvarez J, Keene DR, Bachinger HP, Sakai LY. 2008a. Targeting of bone morphogenetic protein growth factor complexes to fibrillin. J Biol Chem 283:13874-13888.
85. Sengle G, Ono RN, Lyons KM, Bachinger HP, Sakai LY. 2008b. A new model for growth factor activation: Type II receptors compete with the prodomain for BMP-7. J Mol Biol 381: 1025-1039.
86. Sengle G, Ono RN, Sasaki T, Sakai LY. 2011. Prodomains of transforming growth factor beta ( BRI-β) superfamily members specify different functions: Extracellular matrix interactions and growth factor bioavailability. J Biol Chem 286: 5087-5099.
87. Sha X, Yang L, Gentry LE. 1991. Identification and analysis of discrete functional domains in the pro region of pre-protransforming growth factor beta 1. J Cell Biol 114:827-839. (Pubitemid 21909848)
88. Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, Springer TA. 2011. Latent BRI-βeta structure and activation. Nature 474: 343-349.
89. Sopory S, Nelsen SM, Degnin C, Wong C, Christian JL. 2006. Regulation of bone morphogenetic protein-4 activity by sequence elements within the prodomain. J Biol Chem 281: 34021-34031. (Pubitemid 46036611)
90. Susan-ResigaD, Essalmani R, Hamelin J, Asselin MC, Benjannet S, Chamberland A, Day R, Szumska D, Constam D, Bhattacharya S, Prat A, Seidah NG. 2011. Furin is the major processing enzyme of the cardiac-specific growth factor BMP10. J Biol Chem 286:22785-22794.
91. Suzuki S, Marazita ML, Cooper ME, Miwa N, Hing A, Jugessur A, Natsume N, Shimozato K, Ohbayashi N, Suzuki Y, Niimi T, Minami K, Yamamoto M, Altannamar TJ, Erkhembaatar T, Furukawa H, Daack-Hirsch S, L'heureux J, Brandon CA, Weinberg SM, Neiswanger K, Deleyiannis FW, de Salamanca JE, Vieira AR, Lidral AC, Martin JF, Murray JC. 2009. Mutations in BMP4 are associated with subepithelial, microform, and overt cleft lip. Am J Hum Genet 84:406-411.
92. Szumska D, Pieles G, Essalmani R, Bilski M, Mesnard D, Kaur K, Franklyn A, El Omari K, Jefferis J, Bentham J, Taylor JM, Schneider JE, Arnold SJ, Johnson P, Tymowska-Lalanne Z, Stammers D, Clarke K, Neubauer S, Morris A, Brown SD, Shaw-Smith C, Cama A, Capra V, Ragoussis J, Constam D, Seidah NG, Prat A, Bhattacharya S. 2008. VACTERL/caudal regression/Currarino syndrome-like malformations in mice with mutation in the proprotein convertase Pcsk5. Genes Dev 22: 1465-1477. (Pubitemid 351793081)
93. Tassabehji M, Fang ZM, Hilton EN, McGaughran J, Zhao Z, de Bock CE, Howard E, Malass M, Donnai D, Diwan A, Manson FD, Murrell D, Clarke RA. 2008. Mutations in GDF6 are associated with vertebral segmentation defects in Klippel-Feil syndrome. Hum Mutat 29:1017-1027.
94. Ten Dijke P, Arthur HM. 2007. Extracellular control of BRI-β signalling in vascular development and disease. Nat Rev Mol Cell Biol 8:857-869. (Pubitemid 47622560)
95. Thomas JT, PrakashD,Weih K, Moos M, Jr. 2006. CDMP1/GDF5 has specific processing requirements that restrict its action to joint surfaces. J Biol Chem 281:26725-26733. (Pubitemid 44401881)
96. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR. 2002. Inhibition of transforming growth factor-βeta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 62:6021-6025. (Pubitemid 35244446)
97. Urban Z, Hucthagowder V, Schürmann N, Todorovic V, Zilberberg L, Choi J, Sens C, Brown CW, Clark RD, Holland KE, Marble M, Sakai LY, Dabovic B, Rifkin DB, Davis EC 2009. Mutationsin LTBP4 cause a syndrome of impaired pulmonary, gastrointestinal, genitourinary, musculoskeletal, and dermal development.AmJHumGenet 85:593-605.
98. Wakefield LM, Smith DM, Flanders KC, Sporn MB. 1988. Latent transforming growth factor-βeta from human platelets. A high molecular weight complex containing precursor sequences. J Biol Chem 263:7646-7654.
99. WaltonKL,MakanjiY,Chen J,WilceMC,ChanKL,RobertsonDM, Harrison CA. 2010. Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-βeta1 complex. J Biol Chem 285:17029-17037.
100. Walton KL, Makanji Y, Wilce MC, Chan KL, Robertson DM, Harrison CA. 2009. A common biosynthetic pathway governs the dimerization and secretion of inhibin and related transforming growth factor beta ( BRI-β) ligands. J Biol Chem 284: 9311-9320.
101. Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, Wright JF, Zhao L, Sebald SM, Greenspan DS, Lee SJ. 2003. Activation of latent myostatin by the BMP-1/ tolloid family of meta loproteinases. Proc Natl Acad Sci USA 100:15842-15846. (Pubitemid 38021077)
102. Wu HH, Ivkovic S, Murray RC, Jaramillo S, Lyons KM, Johnson JE, Calof AL. 2003. Autoregulation of neurogenesis by GDF11. Neuron 37:197-207. (Pubitemid 36143816)
103. Wu MY, Hill CS. 2009. BRI-βeta superfamily signaling in embryonic development and homeostasis. Dev Cell 16:329-343.
104. Wyatt AW, Osborne RJ, Stewart H, Ragge NK. 2010. Bone morphogenetic protein 7 (BMP7) mutations are associated with variable ocular, brain, ear, palate, and skeletal anomalies. Hum Mutat 31:781-787.
105. Xu Z, Ichikawa N, Kosaki K, Yamada Y, Sasaki T, Sakai LY, Kurosawa H, Hattori N, Arikawa-Hirasawa E. 2010. Perlecan deficiency causes muscle hypertrophy, a decrease in myostatin expression, and changes in muscle fiber composition. Matrix Biol 29:461-470.
106. Yang Z, Mu Z, Dabovic B, Jurukovski V, Yu D, Sung J, Xiong X, Munger JS. 2007. Absence of integrin-mediated BRI-β1 activation in vivo recapitulates the phenotype of BRI-β1-null mice. J Cell Biol 176:787-793. (Pubitemid 46425539)
107. Ye M, Berry-Wynne KM, Asai-Coakwell M, Sundaresan P, Footz T, French CR, Abitbol M, Fleisch VC, Corbett N, Allison WT, Drummond G,Walter MA, Underhill TM,Waskiewicz AJ, et al. 2010. Mutation of the bone morphogenetic protein GDF3 causes ocular and skeletal anomalies. Hum Mol Genet 19: 287-298.
108. Yoshinaga K, Obata H, Jurukovski V, Mazzieri R, Chen Y, Zilberberg L, Huso D, Melamed J, Prijatelj P, Todorovic V, Dabovic B, Rifkin DB. 2008. Perturbation of transforming growth factor ( BRI-β)-βeta1 association with latent BRI-βeta binding protein yields inflammation and tumors. Proc Natl Acad Sci USA 105:18758-18763.
109. Young GD, Murphy-Ullrich JE. 2004. Molecular interactions that confer latency to transforming growth factor-βeta. J Biol Chem 279:38032-38039. (Pubitemid 39195519)
110. Zhang Y, McCormick LL, Gilliam AC. 2003. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graftversus-host disease, a model for human scleroderma. J Invest Dermatol 121:713-719. (Pubitemid 37239112)
111. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, Lacey DL, Goldberg AL, Han HQ. 2010. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142: 531-543.